Inhibitor Therapeutics is a pre-revenue pharmaceutical development company focused on repurposing itraconazole — a generic antifungal — as a chronic oral therapy for basal cell carcinoma nevus syndrome (BCCNS), a rare hereditary condition that causes patients to continuously develop skin tumors throughout their lives. The current standard of care is repeated surgery, which addresses individual lesions but does not prevent new ones from forming. Inhibitor Therapeutics is developing itraconazole as a systemic suppression therapy, arguing that its anti-angiogenic properties and high skin tissue concentration support its use in reducing new lesion development. The company holds orphan drug designation for itraconazole in BCCNS, which could provide seven years of market exclusivity post-approval, and has developed a proprietary micronized formulation (Micro-ITRA, through partner Avior Bio) to support patent filings and reduce substitution risk from generic itraconazole. The company is not building toward self-commercialization — instead, its business model is to build regulatory and IP value, then license, co-develop, or sell the program to a larger pharma or biotech company. Near-term activity is focused on obtaining FDA guidance through a Type C meeting expected in May 2026 on whether existing Phase IIb data can support an NDA under the 505(b)(2) pathway. The company has two full-time employees and outsources essentially all development work.